IMG_0068.jpg
Differentials based on clinical image
analyse_media
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Now I have enough information to provide a thorough differential diagnosis. Here is my analysis:
Differential Diagnosis - Clinical Image Analysis
What the Image Shows
The lesion is on the dorsum of the hand/wrist of what appears to be a child or young person. Key features:
- A dominant lesion: ~1.5-2 cm plaque with a central thick, dark gray-brown/hemorrhagic crust overlying a shallow erosion/ulcer with a "punched-out" appearance and erythematous rim
- Surrounding scattered erythematous papules and papulovesicles, some with pinpoint crusting, in a grouped/herpetiform arrangement
- Signs of excoriation around the lesions
- Lesions are localized to this region (no generalized eruption visible)
Differentials (Most to Least Likely)
1. Ecthyma ⭐ (Top Differential)
The dominant lesion fits ecthyma almost perfectly. It is a deep variant of non-bullous impetigo caused by group A beta-hemolytic streptococci (sometimes with secondary S. aureus contamination).
Key matching features:
- Initial vesiculopustule enlarging and developing a hemorrhagic crust
- "Punched-out" ulceration with erythematous halo
- Lesion size 0.5-3 cm
- Common on extremities
- Associated with insect bite scratching, poor hygiene, trauma
- The scattered surrounding papules may represent satellite early lesions or excoriated insect bites
Dermatology 2-Volume Set 5e describes: "An initial vesiculopustule enlarges (0.5–3 cm in diameter) over several days, and develops a hemorrhagic crust. The ulcer has a 'punched-out' appearance and a purulent, necrotic base."
2. Impetigo (Non-bullous/Crusted) - Superficial variant
The scattered smaller lesions with honey/amber-colored crusting could represent primary non-bullous impetigo (S. aureus or Strep pyogenes). The central dominant lesion may represent an evolved/deeper impetigo lesion. Impetigo does not typically cause deep ulceration, so ecthyma is favored if the central lesion has true ulcer depth.
3. Herpes Simplex Virus (HSV) - Herpetic Whitlow or Primary HSV
The grouped papulovesicles scattered around a central healing/crusted erosion raise herpetic infection on the hand. HSV on the dorsal hand presents with:
- Clustered vesicles on an erythematous base
- Central coalesced lesion with crusting and erosion
- Can be mistaken for impetigo when secondarily crusted
The herpetiform grouping of the surrounding papulovesicles is an important clue for this diagnosis.
4. Herpes Zoster (Shingles)
Less likely without a clear dermatomal distribution, but localized zoster of the hand (C6-C8 dermatome) can present with:
- Grouped vesicles and papulovesicles
- Central erosion/crusted plaque
- Prodromal pain
The scattered non-dermatomal distribution makes this less likely than HSV.
5. Infected Insect Bite / Superinfected Arthropod Reaction
A single insect bite that was traumatized/scratched and subsequently became bacterially superinfected (with Staph or Strep) can evolve into an ecthyma-like picture. The surrounding papules could represent bites at various stages of healing.
6. Orf / Parapoxvirus Infection
If there is any animal (sheep/goat) contact history, orf can present as a single nodule with central crusting on the hand that evolves through papule, target/vesicular, pustular, and regenerative stages. The background scattered papulovesicles would be atypical for this.
7. Ecthyma Gangrenosum
A much more serious differential - associated with Pseudomonas aeruginosa septicemia, typically in immunocompromised patients. The lesion starts as an erythematous macule/hemorrhagic bulla that necroses. Should be considered if the patient is immunosuppressed or systemically unwell - requires urgent workup.
Summary Table
| Diagnosis | Key Supporting Feature | Against |
|---|---|---|
| Ecthyma | Punched-out hemorrhagic crusted ulcer, extremity location, excoriation | - |
| Impetigo (non-bullous) | Honey/amber crust, scattered papules | No deep ulceration |
| HSV (herpetic whitlow/primary) | Grouped vesicles herpetiform pattern | Usually more vesicular, more pain |
| Herpes Zoster | Grouped vesicles | No clear dermatomal strip |
| Superinfected insect bite | Single dominant lesion, traumatized | Background scattered lesions unexplained |
| Orf | Hand location, crusted nodule | Needs animal contact history |
| Ecthyma gangrenosum | Punched-out necrotic lesion | Requires immunocompromise/sepsis |
Recommended Workup
- Wound swab of moist/purulent base for bacterial C&S (Gram stain)
- Tzanck smear or HSV PCR from an intact vesicle if herpetic origin is suspected
- Skin biopsy if diagnosis remains unclear after initial treatment
- HIV / immunosuppression screen if ecthyma gangrenosum is considered
Top pick: Ecthyma (deep streptococcal/staphylococcal infection), with HSV on the hand as a close second given the surrounding grouped vesicular component.
Upadacitinib
Finding Sources
Searching PubMed
upadacitinib JAK1 inhibitor
Searching the Web
upadacitinib Rinvoq mechanism indications dosing 2025
Reading File
Reading File
Reading File
Reading File
Here is a full clinical overview of upadacitinib:
Upadacitinib (Rinvoq)
Drug Class & Mechanism
Upadacitinib is a selective JAK1 inhibitor (oral, extended-release). It blocks JAK1-mediated intracellular signaling downstream of multiple cytokine receptors:
- IL-4, IL-13 (Th2/atopic pathway) - relevant in atopic dermatitis
- IL-6 - relevant in RA, GCA
- IL-12, IL-23 - relevant in spondyloarthropathies
- IFN-γ, GM-CSF
JAK1 inhibition prevents STAT phosphorylation and downstream gene transcription, reducing inflammatory cytokine production. Its selectivity for JAK1 over JAK2/JAK3/TYK2 is intended to reduce the hematologic toxicity seen with pan-JAK inhibitors.
FDA-Approved Indications (as of 2025-2026)
| Indication | Population | Dose |
|---|---|---|
| Rheumatoid Arthritis (RA) | Adults; after inadequate response/intolerance to ≥1 TNF blocker | 15 mg once daily |
| Psoriatic Arthritis (PsA) | Adults + children ≥2 yrs; after ≥1 TNF blocker failure | 15 mg once daily |
| Atopic Dermatitis (AD) | Adults + children ≥12 yrs weighing ≥40 kg | 15 mg OD; can escalate to 30 mg OD |
| Ulcerative Colitis (UC) | Adults (after ≥1 systemic therapy; TNF blockers inadvisable) | Induction: 45 mg OD x8 wks; Maintenance: 30 mg OD |
| Crohn's Disease (CD) | Adults (same step criteria as UC, updated Oct 2025) | Induction: 45 mg OD x12 wks; Maintenance: 15 mg OD (30 mg for severe) |
| Ankylosing Spondylitis (AS) | Adults | 15 mg once daily |
| Non-radiographic axial SpA (nr-axSpA) | Adults | 15 mg once daily |
| Polyarticular JIA (PJIA) | Children ≥2 yrs; after ≥1 TNF blocker failure | Weight-based (use Rinvoq LQ oral solution) |
| Giant Cell Arteritis (GCA) | Adults | Newly approved April 2025 |
Note: In AD, patients ≥65 years are capped at 15 mg daily regardless of response.
Pharmacokinetics
- Formulation: Extended-release oral tablet (15 mg, 30 mg, 45 mg); oral solution 1 mg/mL (Rinvoq LQ) for pediatric use
- Tmax: 2-3 hours
- Half-life: 10-12.5 hours
- Metabolism: Primarily CYP3A4, minor CYP2D6
- Key interactions:
- Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole): increase exposure - dose reduce
- Strong CYP3A4 inducers (e.g. rifampin): decrease exposure - avoid combination
Efficacy Highlights
- RA: In phase III trials (SELECT program), ~65-75% of patients achieved ACR20. Efficacy was comparable to adalimumab; superior to methotrexate monotherapy.
- Atopic Dermatitis: ~65-75% of patients achieved EASI-75. Outperformed dupilumab in head-to-head trials (Heads Up trial) on EASI-90 and IGA 0/1 at 16 weeks.
- UC/CD: Rapid induction of remission in biologic-naive and biologic-experienced patients. Particularly useful in acute severe UC.
- AxSpA/AS: Significant improvements in BASDAI, ASDAS, and MRI inflammation scores per recent systematic review (PMID 39162272).
- GCA: First oral agent approved for GCA; reduces relapse rates and steroid burden.
Safety Profile
Black Box Warnings (FDA Boxed Warning)
- Serious Infections - bacterial, mycobacterial, fungal, viral (TB, herpes zoster, opportunistic)
- Mortality - increased all-cause mortality in RA patients ≥50 yrs with ≥1 CV risk factor (class effect, from tofacitinib ORAL Surveillance data)
- Malignancy - increased lymphoma, lung cancer risk (class data from tofacitinib; extrapolated)
- MACE (Major Adverse Cardiovascular Events) - MI, stroke, CV death
- Thrombosis - DVT, PE, arterial thrombosis
Most Common Adverse Events (from integrated phase III RA safety data at 15 mg)
| Event | Rate per 100 pt-yrs |
|---|---|
| Serious infections (SIEs) | 3.8 |
| Herpes zoster | 3.7 |
| Hepatic disorders (transaminase elevation) | 14.4 |
| CPK elevation | 6.1 |
| Active/latent TB | 2.2 |
| MACE | 0.6 |
| VTE | 0.6 |
| GI perforations | 0.2 |
| Malignancies | 0.9 |
Rates of herpes zoster and CPK elevations were higher with upadacitinib than with both methotrexate and adalimumab. - Firestein & Kelley's Textbook of Rheumatology
Other notable effects:
- Reduction in NK cells
- Acne (particularly with 30 mg dose in AD)
- Neutropenia, anemia (monitor CBC)
- Lipid elevations (monitor lipid panel)
- GI perforations (especially with concurrent NSAIDs or steroids)
Pre-treatment Screening
Before starting upadacitinib:
- TB screening (PPD or IGRA + CXR)
- Hepatitis B/C serology
- CBC, CMP, lipid panel
- Pregnancy test (teratogenic - avoid in pregnancy)
- Update live vaccines (live vaccines are contraindicated during therapy)
- Assess CV risk factors, personal/family history of malignancy
Off-label Dermatologic Uses (2025)
A growing body of evidence supports upadacitinib for several off-label skin conditions, per systematic review (PMID 39920358):
- Hidradenitis suppurativa
- Prurigo nodularis
- Alopecia areata
- Vitiligo
- Pyoderma gangrenosum
- Hailey-Hailey disease
- Erythrodermic mycosis fungoides
- Disseminated granuloma annulare
- SAPHO syndrome
Contraindications
- Active serious infection
- Pregnancy (category X equivalent - animal teratogenicity)
- Do not combine with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants (cyclosporine, azathioprine)
- Caution/avoid in patients with known malignancy, history of thrombosis, or high CV risk
This is a shared conversation. Sign in to Orris to start your own chat.